Is Clearside Biomedical, Inc. overvalued or undervalued?

As of 14 August 2023, the valuation grade for Clearside Biomedical, Inc. has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company appears to be overvalued given its negative P/E ratio, a price to book value of -1.33, and an EV to EBITDA ratio of -3.96. These metrics suggest that the company's financial performance is not only poor but also deteriorating relative to its peers.
In comparison to its peers, Kinnate Biopharma, Inc. has a fair valuation with a P/E of -1.1313 and an EV to EBITDA of 0.2381, while Veru, Inc. also carries a risky valuation with a P/E of -2.2975 and an EV to EBITDA of -1.7079. The stark contrast in these ratios highlights Clearside's challenging position in the market. Additionally, the company's stock has underperformed significantly over the past year, with a return of -24.04% compared to a 10.26% gain in the S&P 500, reinforcing the notion that it is currently overvalued.